康寧傑瑞製藥-B(09966.HK)兩新藥臨床試驗初步結果摘要獲ASCO年會接受以海報形式呈列
康寧傑瑞製藥-B(09966.HK)公布,KN026(一種基於Fc的抗HER2雙特異性單克隆抗體BsAb於中國針對HER2陽性轉移性乳腺癌患者的首次用於人體的開放標籤I期臨床試驗)的療效、安全性和藥代動力學(PK)的初步結果;及KN046(一種雙特異性免疫檢查點抑制劑)於中國針對之前免疫檢查點抑制劑(ICI)失效的患者的劑量遞增及擴展Ia/Ib期臨床試驗的初步療效和安全性數據摘要,已獲即將召開的2020年美國臨床腫瘤學會(ASCO)年會接受以海報形式呈列。
集團指,目前KN026正在中國進行數項II期臨床試驗,並在美國進行一項I期臨床試驗。KN026已在晚期乳腺癌患者中表現出良好的初步療效。KN046目前正在進行對NSCLC、三陰乳腺癌(TNBC)、食管鱗狀細胞癌(ESCC)及胰腺癌的多項II期臨床試驗。該等臨床試驗結果將於各種場合發布。KN046有望成為第二代免疫腫瘤治療藥物的基石藥物之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.